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Antibacterial activity of fractions from three Chumash medicinal plant
extracts and in vitro inhibition of the enzyme enoyl reductase by the flavonoid
jaceosidin
We have investigated the in vitro antibacterial bioactivity of dichloromethane-soluble fractions of
Artemisia californica, Trichostema lanatum, Salvia apiana, Sambucus nigra ssp. cerulea and
Quercus agrifolia Née against a ΔtolC mutant strain of E. coli. These plants are traditional
medicinal plants of the Chumash Native Americans of Southern California. Bioassay-guided
fractionation led to the isolation of three flavonoid compounds from A. californica: jaceosidin (1),
jaceidin (2), and chrysoplenol B (3). Compounds 1 and 2 exhibited anti-bacterial activity against
E. coli ΔtolC in liquid cultures. The in vitro activity of 1 against the enoyl reductase enzyme
(FabI) was measured using a spectrophotometric assay and found to completely inhibit FabI
activity at a concentration of 100 μM. However, comparison of MIC values for 1-3 against E.
coli ΔtolC and an equivalent strain containing a plasmid constitutively expressing fabI did not
reveal any selectivity for FabI in vivo.

Keywords: Artemisia californica, enoyl reductase, jaceosidin, Native American plants, antimicrobial,
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1. Introduction
Fatty acids are essential molecules in all organisms and there are two types of biosynthetic
mechanisms for producing fatty acids in nature. Type 1 fatty acid synthase (FAS I) is a
multifunctional enzyme complex found in animals and plants that contains all of the machinery
needed to make fatty acids in a single multi-enzyme complex (Chirala & Wakil 2004). In
contrast to this unified system, bacteria use the Type 2 fatty acid synthase pathway (FAS II) to
synthesize fatty acids which is composed of discrete enzymes that produce fatty acids in a series
of individual reactions and is considered to be an excellent focus for antibacterial drug discovery
(Parsons & Rock 2011; Wang & Ma 2013).
Previous studies of the antibacterial properties of plant metabolites have demonstrated
that many polyphenolic and terpenoid compounds from plants inhibit bacterial FAS II enzymes
(Zhang & Rock 2004; Tasdemir et al. 2006). These findings strongly support the idea that
targeting fatty acid biosynthesis in general, and the FASII enzyme enoyl reductase (FabI in

Escherichia coli) in particular, may be promising strategies for the development of new
antibiotics (Parsons & Rock 2011; Wang & Ma 2013). The purpose of the study was to
investigate the antibacterial properties of some traditional medicinal plants of the Chumash
Native Americans and identify compounds from these plants that inhibit the enzyme FabI. We
screened fractions from a panel of these plants for antibacterial activity and we describe the
isolation of three flavonoid compounds (1-3) with antibacterial activity from Artemisia
californica. The flavonoid jaceosidin (1) exhibited in vitro inhibitory activity against FabI but
no selectivity against the enzyme was observed in vivo.

2. Results and Discussion
A group of plants native to the coastal region of Southern California were selected for screening
of their potential antibacterial properties based on documented reports of their traditional use as
medicinal treatments by the Chumash people, a native tribal group indigenous to the coastal
region of Southern California in the United States (Timbrook 2007). The plants selected for this
study were Artemisia californica Less. (Asteraceae), Trichostema lanatum Benth. (Lamiaceae),
Salvia apiana Jeps. (Lamiaceae), Sambucus nigra ssp. cerulea (Adoxaceae) and Quercus
agrifolia Née (Fagaceae) (Table S1). Two of the plants that were screened also belong to genera
(Artemisia and Salvia) with long traditions of medicinal use in cultures throughout the world
(Tan et al. 1998; Wu et al. 2012).
Leaves and stems from each plant specimen were collected in Malibu, California and the
dichloromethane-soluble (DCM) fraction of each extract was generated as described in the
Supplementary Materials. The DCM fractions were screened for antibacterial activity against a
ΔtolC mutant strain of the gram-negative bacterium E. coli. The tolC knockout mutant reduces
the activity of TolC-dependent multidrug efflux pumps that bind foreign molecules such as
antibiotics and move them out of the cell, thus protecting the bacterium from poisonous
molecules (Jackowski et al. 2002). The DCM fractions of S. nigra ssp. cerulea and Q. agrifolia
did not exhibit any antibacterial activity, but fractions of A. californica, T. lanatum and S. apiana
inhibited the growth of E. coli ΔtolC (Table S1).
Based on the results of the initial screening, the DCM fraction from A. californica was
further fractionated by reverse-phase HPLC and bioassay-guided fractionation was used to

isolate the flavonoids jaceosidin (1), jaceidin (2), and chrysoplenol B (3) (Figure 1). Comparison
of 1H and 13C NMR spectra to published values confirmed the identity of these compounds
(Martínez et al. 1987; Sy & Brown 1998; Flamini et al. 2001; Huong et al. 2005). In light of
other studies that have demonstrated that flavonoids and other plant polyphenols are effective
inhibitors of FabI (Zhang & Rock 2004), a two-stage bioassay was developed to compare the
activity of 1-3 against the E. coli ΔtolC control strain and against the same strain engineered to
constitutively express the fabI gene from a plasmid (E. coli ΔtolC [fabI]). Decreased growth
inhibition of the [fabI] strain compared to the control strain is an indicator that samples may be
inhibitors of the FabI enzyme since excess amounts of FabI reduce the antimicrobial effect of
active samples (Heath et al. 1998). None of the isolated compounds demonstrated greater
potency against the ΔtolC control strain compared to the [fabI] strain (Table 1). The minimum
inhibitory concentration (MIC) for 1 and 2 against both strains was 10 μM and 50 μM,
respectively, while 3 did not exhibit any significant inhibitory activity. These results suggested
that that these compounds did not inhibit FabI in vivo. All three compounds were also tested for
inhibitory activity against a wild-type strain of E. coli which did not contain the tolC mutation;
no inhibition of the E. coli WT strain was observed upon treatment with 1-3 at concentrations of
up to 100 μM. All three E. coli strains were also treated with triclosan as a positive control. The
large increase in the MIC of triclosan against the [fabI] strain (0.025 μM) compared to the ΔtolC
strain (0.007 μM) showed that compounds that inhibit FabI exhibit decreased potency in the
[fabI] strain, in accordance with other reports (Heath et al. 1998).
Although 1-3 did not exhibit any apparent selectivity against FabI in vivo, 1 was tested
for FabI inhibitory activity using an in vitro assay (Figure 2) since other reports suggest that
many flavonoids are effective inhibitors of FabI (Zhang & Rock 2004; Tasdemir et al. 2006).
Compounds 2 and 3 were not tested in this assay due to a lack of materials. Inhibition of FabI
activity by 1 was complete at a concentration of 100 μM and the estimated IC50 value was 75
μM. Inhibition of FabI with triclosan (30 μM) as a positive control resulted in only 30% of the
activity of the uninhibited enzyme (Figure 2). These results, in combination with the absence of
any decreased sensitivity to jaceosidin in E. coli ΔtolC [fabI] (Table 1, Figure S8), provide
strong evidence that although 1 does inhibit FabI, its full antibacterial properties probably arise
from more than one mechanism of action since the MIC for 1 was lower than the concentrations
used to inhibit FabI in vitro.

Compound 1 has been previously identified in other species in the Asteracae family and
has been reported to possess anti-inflammatory (Clavin et al. 2007), antibacterial (Barnes et al.
2013) and antiallergenic (Min et al. 2009) activity as well as activity in a variety of other
bioassays related to cell signaling (Goettert et al. 2010; Nam et al. 2013; Lee et al. 2013).
However, this study is the first time it has been identified in A. californica and it is the first
report of its inhibitory activity against enzymes in the FASII pathway. Our findings in this study
corroborate the conclusions of other studies that although plant polyphenol compounds can
inhibit the FabI enzyme it is likely not their only mechanism of inhibiting bacterial growth
(Zhang & Rock 2004).

3. Conclusions
In this study, extracts from a panel of Native American traditional medicinal plants were
screened for antibacterial activity. We found that DCM fractions from A. californica, T. lanatum
and S. apiana inhibited the growth of E. coli ΔtolC. Bioassay-guided fractionation of the DCM
fraction from A. californica led to the isolation of three flavonoid compounds: jaceosidin (1),
jaceidin (2), and chrysoplenol B (3). The flavonoid 1 exhibited in vitro inhibitory activity
against the enoyl reductase enzyme (FabI) with an estimated IC50 of 75 μM. However,
comparison of MICs for 1-3 against an E. coli ΔtolC control strain and an equivalent strain
containing a plasmid constitutively expressing fabI (10 μM, 50 μM and >100 μM for 1, 2 and 3,
respectively, in both strains) did not reveal any selectivity for FabI in vivo. Although the
compounds identified in this study are not new, this is the first reputable report of any flavonoids
from A. californica. Additionally, these findings support the proposal that while flavonoids may
inhibit enoyl reductase enzymes their antibacterial activities probably arise from more than one
mechanism of action.

Supplementary Material
Experimental methods with 1H and 13C NMR spectra of 1-3 and bacterial growth inhibition
curves are available in the Supplementary Material.
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Table 1. Summary of MIC data for flavonoids from A. californica
Bacterial strain
E. coli WT
E. coli ΔtolC
E. coli ΔtolC [fabI]

triclosan
0.100 μM
0.007 μM
0.025 μM

1
>100 μM
10 μM
10 μM

2
>100 μM
50 μM
50 μM

3
>100 μM
>100 μM
>100 μM

Figure Captions

Figure 1. Chemical structures of jaceosidin (1), jaceidin (2), and chrysoplenol B (3).

Figure 2. An enzyme inhibition assay was performed to measure the ability of jaceosidin (1) to
inhibit FabI. The relative enzyme activity was expressed as a percentage of the negative vehicle
control (N = 10). The relative activity of FabI was determined from the rate of the enzymatic
reduction of butenoyl-CoA. Treatment with 1 at a concentration of 30 μM (N = 4) did not
significantly reduce FabI activity but treatment with 1 at 50 μM (N = 6) significantly reduced
FabI activity while treatment at 100 μM (N = 3) eliminated all observed enzyme activity (P
values shown from Student’s t-test comparing each treatment to control).

